Eli Lilly and Novo Nordisk Lead $100 Billion Race for Anti-Obesity Drug Market
• The anti-obesity drug market could be worth $100 billion by 2030. Eli Lilly's Zepbound and Novo Nordisk's Wegovy are currently the top selling weight-loss drugs.
• Zepbound helped patients lose more weight than Wegovy in clinical trials, but both Eli Lilly and Novo Nordisk are working on oral weight-loss treatments.
• Pfizer and AstraZeneca are working on potential new weight-loss drugs that could compete with Zepbound and Wegovy in the future.
• Roche recently acquired a company working on a once-daily injectable weight-loss drug, but it likely won't be on the market until 2030.
• Eli Lilly and Novo Nordisk are currently the best investments for the weight-loss drug market based on their current products, while the other companies are bigger long shots.